PMB Specific Neutra™ Antibody Products

Are you struggling with prolonged antibiotic development timelines or antimicrobial resistance challenges? Creative Biolabs' PMB specific Neutra™ antibody products leverage advanced protein engineering and validated functional assays to accelerate the discovery of precision therapies targeting PMB-resistant pathogens.

Introduction to PMB

Polymyxin B (PMB), a cyclic cationic polypeptide antibiotic, is primarily used as a last-line defense against multidrug-resistant Gram-negative bacterial infections. Its mechanism involves binding to lipopolysaccharides (LPS) on bacterial membranes, disrupting membrane integrity and causing cell lysis. However, rising resistance mechanisms, such as LPS modification and efflux pump activation, have severely limited PMB's clinical utility.

Fig.1 Chemical structures of PMB and the PMB based imaging and photosensitizing agents targeting Gram-negative bacteria.¹

• Structural Insights

The structure of PMB is composed of a heptapeptide ring linked to a tripeptide side chain with a fatty acid tail. This amphipathic design facilitates interaction with the hydrophobic lipid A moiety of LPS. Key residues (e.g., Dab-threonine-Dab sequence) mediate electrostatic interactions with phosphate groups on LPS, enabling membrane permeabilization. Structural optimization of antibodies targeting these regions is crucial to overcoming resistance.

• Associated Signaling Pathways

PMB resistance mechanisms intersect with bacterial stress-response pathways:

- PmrA/PmrB System: Upregulates LPS modification genes (e.g., arnT), reducing PMB binding affinity.

- PhoP/PhoQ System: Activates lipid A remodeling under low magnesium conditions, enhancing bacterial survival.

- Efflux Pumps: Overexpression of systems like AcrAB-TolC expels PMB, diminishing intracellular accumulation.

• Clinical Implications

PMB-resistant infections, particularly in Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, are linked to high mortality in immunocompromised patients, ventilator-associated pneumonia, and sepsis. The rise of pan-resistant strains underscores the urgent need for innovative therapies.

Applications of Anti-PMB Neutralizing Antibodies

• Therapeutic Intervention in Resistant Infections

Anti-PMB antibodies restore antibiotic sensitivity by blocking LPS modifications. In combination therapies, they synergistically enhance the potency of traditional antibiotics, reducing required dosages and mitigating nephrotoxicity risks, a critical advantage in patient care.

• Prophylactic Use in High-Risk Populations

Prophylactic administration in critically ill patients preemptively neutralizes bacterial endotoxins, lowering sepsis incidence. This approach is particularly beneficial for post-surgical or transplant recipients vulnerable to nosocomial infections, offering a novel shield against potentially fatal complications.

• Diagnostic and Biomarker Development

Anti-PMB antibodies serve as sensitive probes in ELISA-based assays to detect PMB-resistant strains in clinical samples. They also quantify LPS levels in serum, providing real-time monitoring of endotoxemia during sepsis management, facilitating personalized treatment adjustments and improved patient outcomes.

Anti-PMB Antibodies

Creative Biolabs' anti-PMB neutralizing antibodies are engineered to target conserved epitopes critical for LPS binding, circumventing resistance mechanisms. Key features include:

• High Specificity: Antibodies selectively bind PMB-LPS complexes without cross-reacting with human cell membranes.
• Functional Validation: Demonstrated efficacy in in vitro bactericidal assays and in vivo sepsis models.
• Dual Action: Neutralize PMB's toxicity while preserving immunomodulatory effects against endotoxins.

Creative Biolabs provides PMB specific antibody portfolio that combines scientific rigor with translational relevance, offering tools to combat antimicrobial resistance. Contact our scientific team today to explore customized solutions for your research or therapeutic programs.

REFERENCE

1. Wu, Minghao, et al. "Molecular engineering of polymyxin B for imaging and treatment of bacterial infections." Frontiers in Chemistry 9 (2022): 809584. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fchem.2021.809584